ESCAPE30 our new development strategy
ESCAPE30: Excellence in Services as CDMO for monoclonal Antibodies and therapeutic Proteins in Europe , by 2030
ESCAPE30 our new development strategy
In November 2022 the leadership team of LFB BIOMANUFACTURING met with aim to precise the strategic path of the company, referred to as ESCAPE30, and its associated long term priorities
LFB BIOMANUFACTURING targets Excellence in Services as CDMO for monoclonal Antibodies and therapeutic Proteins in Europe; this will contribute to the national sovereignty in the field.
Based on a strong background, LFB foresees to harness its scientific heritage to satisfy the world wide patient needs by providing CDMO top level services for development and manufacturing of innovative products.
